Literature DB >> 24184127

Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters.

Michael K Lo1, Brian H Bird2, Anasuya Chattopadhyay3, Clifton P Drew4, Brock E Martin2, Joann D Coleman2, John K Rose3, Stuart T Nichol2, Christina F Spiropoulou5.   

Abstract

Nipah virus (NiV) continues to cause outbreaks of fatal human encephalitis due to spillover from its bat reservoir. We determined that a single dose of replication-defective vesicular stomatitis virus (VSV)-based vaccine vectors expressing either the NiV fusion (F) or attachment (G) glycoproteins protected hamsters from over 1000 times LD50 NiV challenge. This highly effective single-dose protection coupled with an enhanced safety profile makes these candidates ideal for potential use in livestock and humans. Published by Elsevier B.V.

Entities:  

Keywords:  Hamster; Henipavirus; Nipah; Single-dose; VSV; Vaccine

Mesh：

Substances：

Year:  2013        PMID： 24184127      PMCID： PMC3874889          DOI： 10.1016/j.antiviral.2013.10.012

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  34 in total

1.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

2.  Nipah virus: a recently emergent deadly paramyxovirus.

Authors:  K B Chua; W J Bellini; P A Rota; B H Harcourt; A Tamin; S K Lam; T G Ksiazek; P E Rollin; S R Zaki; W Shieh; C S Goldsmith; D J Gubler; J T Roehrig; B Eaton; A R Gould; J Olson; H Field; P Daniels; A E Ling; C J Peters; L J Anderson; B W Mahy
Journal:  Science       Date:  2000-05-26       Impact factor: 47.728

3.  A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.

Authors:  Katharine N Bossart; Barry Rockx; Friederike Feldmann; Doug Brining; Dana Scott; Rachel LaCasse; Joan B Geisbert; Yan-Ru Feng; Yee-Peng Chan; Andrew C Hickey; Christopher C Broder; Heinz Feldmann; Thomas W Geisbert
Journal:  Sci Transl Med       Date:  2012-08-08       Impact factor: 17.956

Review 4.  A treatment for and vaccine against the deadly Hendra and Nipah viruses.

Authors:  Christopher C Broder; Kai Xu; Dimitar B Nikolov; Zhongyu Zhu; Dimiter S Dimitrov; Deborah Middleton; Jackie Pallister; Thomas W Geisbert; Katharine N Bossart; Lin-Fa Wang
Journal:  Antiviral Res       Date:  2013-07-06       Impact factor: 5.970

5.  Molecular characterization of Nipah virus, a newly emergent paramyxovirus.

Authors:  B H Harcourt; A Tamin; T G Ksiazek; P E Rollin; L J Anderson; W J Bellini; P A Rota
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

Review 6.  Epidemiology of henipavirus disease in humans.

Authors:  Stephen P Luby; Emily S Gurley
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

7.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Comparison of the pathogenicity of Nipah virus isolates from Bangladesh and Malaysia in the Syrian hamster.

Authors:  Blair L DeBuysscher; Emmie de Wit; Vincent J Munster; Dana Scott; Heinz Feldmann; Joseph Prescott
Journal:  PLoS Negl Trop Dis       Date:  2013-01-17

9.  Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge.

Authors:  Misako Yoneda; Marie-Claude Georges-Courbot; Fusako Ikeda; Miho Ishii; Noriyo Nagata; Frederic Jacquot; Hervé Raoul; Hiroki Sato; Chieko Kai
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

10.  Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months.

Authors:  Jackie A Pallister; Reuben Klein; Rachel Arkinstall; Jessica Haining; Fenella Long; John R White; Jean Payne; Yan-Ru Feng; Lin-Fa Wang; Christopher C Broder; Deborah Middleton
Journal:  Virol J       Date:  2013-07-16       Impact factor: 4.099
View more
  26 in total

1.  Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Authors:  Nicholas J Lennemann; Andrew S Herbert; Rachel Brouillette; Bethany Rhein; Russell A Bakken; Katherine J Perschbacher; Ashley L Cooney; Catherine L Miller-Hunt; Patrick Ten Eyck; Julia Biggins; Gene Olinger; John M Dye; Wendy Maury
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

2.  Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.

Authors:  Blair L DeBuysscher; Dana Scott; Andrea Marzi; Joseph Prescott; Heinz Feldmann
Journal:  Vaccine       Date:  2014-03-12       Impact factor: 3.641

3.  Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.

Authors:  Anthony N van den Pol; Guochao Mao; Anasuya Chattopadhyay; John K Rose; John N Davis
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

4.  Hendra virus and Nipah virus animal vaccines.

Authors:  Christopher C Broder; Dawn L Weir; Peter A Reid
Journal:  Vaccine       Date:  2016-05-04       Impact factor: 3.641

5.  A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.

Authors:  Alex B Ryder; Linda Buonocore; Leatrice Vogel; Raffael Nachbagauer; Florian Krammer; John K Rose
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

6.  Rhabdovirus-based vaccine platforms against henipaviruses.

Authors:  Drishya Kurup; Christoph Wirblich; Heinz Feldmann; Andrea Marzi; Matthias J Schnell
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

7.  An Immunoinformatics Prediction of Novel Multi-Epitope Vaccines Candidate Against Surface Antigens of Nipah Virus.

Authors:  Md Mahfuzur Rahman; Joynob Akter Puspo; Ahmed Ahsan Adib; Mohammad Enayet Hossain; Mohammad Mamun Alam; Sharmin Sultana; Ariful Islam; John D Klena; Joel M Montgomery; Syed M Satter; Tahmina Shirin; Mohammed Ziaur Rahman
Journal:  Int J Pept Res Ther       Date:  2022-06-23       Impact factor: 2.191

8.  Evaluation of a Single-Dose Nucleoside-Modified Messenger RNA Vaccine Encoding Hendra Virus-Soluble Glycoprotein Against Lethal Nipah virus Challenge in Syrian Hamsters.

Authors:  Michael K Lo; Jessica R Spengler; Stephen R Welch; Jessica R Harmon; JoAnn D Coleman-McCray; Florine E M Scholte; Punya Shrivastava-Ranjan; Joel M Montgomery; Stuart T Nichol; Drew Weissman; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

9.  Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.

Authors:  Chad E Mire; Krista M Versteeg; Robert W Cross; Krystle N Agans; Karla A Fenton; Michael A Whitt; Thomas W Geisbert
Journal:  Virol J       Date:  2013-12-13       Impact factor: 4.099

10.  Vaccines to Emerging Viruses: Nipah and Hendra.

Authors:  Moushimi Amaya; Christopher C Broder
Journal:  Annu Rev Virol       Date:  2020-09-29       Impact factor: 10.431
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.